A61P 5/38
Drugs for disorders of the endocrine system: of the suprarenal hormones
Official title: of the suprarenal hormones
A61P5/38 (Drugs for disorders of the endocrine system: of the suprarenal hormones) appears on 1,443 US grants and 2,070 published applications in this corpus.
Search patents in A61P- Granted patents
- 1,443
- Published applications
- 2,070
- Assignees
- 769
- Inventors
- 4,093
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 3 | 0 |
| 1978 | 2 | 0 |
| 1979 | 5 | 0 |
| 1980 | 4 | 0 |
| 1981 | 6 | 0 |
| 1982 | 5 | 0 |
| 1983 | 2 | 0 |
| 1984 | 8 | 0 |
| 1985 | 8 | 0 |
| 1986 | 8 | 0 |
| 1987 | 6 | 0 |
| 1988 | 3 | 0 |
| 1989 | 8 | 0 |
| 1990 | 8 | 0 |
| 1991 | 10 | 0 |
| 1992 | 7 | 0 |
| 1993 | 8 | 0 |
| 1994 | 6 | 0 |
| 1995 | 8 | 0 |
| 1996 | 8 | 0 |
| 1997 | 8 | 0 |
| 1998 | 13 | 0 |
| 1999 | 10 | 0 |
| 2000 | 15 | 0 |
| 2001 | 19 | 9 |
| 2002 | 27 | 36 |
| 2003 | 23 | 66 |
| 2004 | 20 | 108 |
| 2005 | 24 | 82 |
| 2006 | 40 | 98 |
| 2007 | 42 | 121 |
| 2008 | 34 | 97 |
| 2009 | 56 | 155 |
| 2010 | 67 | 139 |
| 2011 | 77 | 120 |
| 2012 | 91 | 102 |
| 2013 | 100 | 87 |
| 2014 | 72 | 94 |
| 2015 | 65 | 90 |
| 2016 | 58 | 109 |
| 2017 | 88 | 87 |
| 2018 | 60 | 77 |
| 2019 | 66 | 78 |
| 2020 | 59 | 57 |
| 2021 | 45 | 66 |
| 2022 | 43 | 47 |
| 2023 | 26 | 42 |
| 2024 | 32 | 44 |
| 2025 | 27 | 31 |
| 2026 | 10 | 28 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods and compositions for treating glucocorticoid excess15 Sep 2026US 12,734,155 B2Sparrow Pharmaceuticals, Inc.
- Methods and compositions for treating glucocorticoid excess15 Sep 2026US 12,734,156 B2Sparrow Pharmaceuticals, Inc.
- Treatment of adrenocortical carcinoma with selective glucocorticoid receptor modulators (SGRMs) and antibody checkpoint inhibitors9 Jun 2026US 12,648,943 B2Corcept Therapeutics, Inc.
- Fc region variant2 Jun 2026US 12,643,937 B2Chugai Seiyaku Kabushiki Kaisha
- Recombinant interferon with changed spatial configuration26 May 2026US 12,636,347 B2
- Dosage regime of crinecerfont for treating congenital adrenal hyperplasia in a pediatric subject1 Oct 2026US 2026/0294876 A1Neurocrine Biosciences, Inc.
- Dosage regime of crinecerfont for treating congenital adrenal hyperplasia24 Sep 2026US 2026/0284015 A1Neurocrine Biosciences, Inc.
- Pharmaceutically acceptable salt and crystal form of 1,4-dihydro-1,6-naphthyridine amide compound and preparation method therefor10 Sep 2026US 2026/0265249 A1Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Methods of treating congenital adrenal hyperplasia27 Aug 2026US 2026/0248812 A1Spruce Biosciences, Inc.
- Methods of treating congenital adrenal hyperplasia27 Aug 2026US 2026/0248813 A1Spruce Biosciences, Inc.
Most cited
By later US patents
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions616US 6,569,463 B2Lipocine Inc. · 2003
- Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents342US 6,309,663 B1Lipocine Inc. · 2001
- Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations234US 6,046,177 ACydex, Inc. · 2000